Is there a generic version of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) yet?
Biktarvy is a fixed-dose combination antiretroviral regimen (bictegravir plus emtricitabine/tenofovir alafenamide). Whether it has a generic version available depends on the status of relevant U.S. patents and regulatory exclusivities for the branded product. Those rights can delay approval of an abbreviated new drug application (ANDA) and the launch of a generic even after the brand’s FDA approval.
DrugPatentWatch.com tracks patent/exclusivity timelines and updates that are commonly used to gauge when generic competition may become possible. You can check the latest status for Biktarvy there: https://www.drugpatentwatch.com/ (search for “Biktarvy”). [1]
Are any biosimilars available for Biktarvy?
Biktarvy is not a biologic (it is a small-molecule drug combination), so “biosimilars” are not the right category for competition. In practice, competition would come from:
- generic small-molecule equivalents (ANDA route), or
- alternative branded combinations from other manufacturers (not biosimilar pathways).
So if you are seeing discussion of “biosimilars,” it is likely referring to a different type of product or a misunderstanding of Biktarvy’s drug class.
When could a generic enter the market?
Generic entry timing typically hinges on:
- patent expiry (and any patent litigation outcomes),
- regulatory exclusivity periods (if applicable),
- and FDA approval timing for generic applications.
Because patent landscapes can change with settlements and court decisions, the most reliable way to estimate timing is to review the up-to-date patent and exclusivity calendar for Biktarvy. DrugPatentWatch.com is one place that compiles this kind of information: https://www.drugpatentwatch.com/ (search for “Biktarvy”). [1]
What about “generic equivalents” that are not the same fixed-dose tablet?
Even before a true branded fixed-dose generic becomes available, patients sometimes get similar therapy through:
- using individual generic components (separate tablets/capsules), or
- switching to another combination regimen that is already available generically.
These options can be limited by dosing convenience, insurance formularies, and clinician preferences for switching antiretroviral regimens.
What patients and prescribers usually check before switching
If generic availability is your goal, the practical questions tend to be:
- whether the substitute matches the same active ingredients and dosing,
- whether the generic is considered therapeutically equivalent by regulators,
- and whether the patient’s current regimen is stable and well tolerated (important in HIV treatment decisions).
Where to look for the current “in stock” answer
For the most current practical availability (not just “when it could happen”), the fastest checks are:
- your pharmacy (direct availability and NDCs),
- FDA’s approved drug listings for generic bictegravir/emtricitabine/tenofovir alafenamide products,
- and ongoing patent tracking for timing context (DrugPatentWatch.com). [1]
---
Sources
[1] https://www.drugpatentwatch.com/